Consolidated Balance Sheets - USD ($)	Sep. 30, 2020	Jun. 30, 2020
CURRENT ASSETS
Cash	$ 21,125	$ 15,282
Prepaid expenses and other assets	10,349	13,361
Tax refunds receivable	604	3,317
Accounts receivable, net	23,602	9,858
Note receivable, related party	10,300	6,878
Total Current Assets	65,980	48,696
Property and Equipment, Net	1,802	1,922
Operating lease right-of-use asset	80,989	74,710
TOTAL ASSETS	148,771	125,328
LIABILITIES
Accounts payable and accrued expenses	145,778	119,246
Accrued interest - related party	48,320	42,359
Notes payable - related party	679,479	618,568
Current portion of operating lease liability	18,131	11,312
Total Current Liabilities	891,708	791,485
Operating lease liability, net of current portion	63,363	63,721
Total Liabilities	955,071	855,206
STOCKHOLDERS' DEFICIT
Preferred stock, no par value; 10,000,000 shares authorized, -0- shares issued and outstanding	0	0
Common stock, no par value; 250,000,000 shares authorized 203,355,598 and 203,355,598 shares issued and 203,301,842 and 203,301,842 shares outstanding respectively	33,027,676	33,027,676
Additional paid-in capital	4,513,328	4,513,328
Treasury stock, at cost	(19,387)	(19,387)
Accumulated other comprehensive income	91,474	91,907
Accumulated deficit	(37,771,313)	(37,696,425)
Total Sangui Biotech International, Inc's stockholders' defict	(158,222)	(82,901)
Non-controlling interest	(648,078)	(646,977)
Total Stockholders' Deficit	(806,300)	(729,878)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 148,771	$ 125,328